(secondQuint)Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers.

 The purpose of this study is to compare the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE vaccine.

 The vaccine consists of the recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (Glucopyranosyl Lipid A - Stable Emulsion) and is being developed for the prevention of leprosy disease.

 This is a first-in-human study and will be conducted in healthy adult subjects.

 Two dose levels of the vaccine (2 1/2g LEP-F1 + 5 1/2g GLA-SE and 10 1/2g LEP-F1 + 5 1/2g GLA-SE) will be given by intramuscular administration on study Days 0, 28, and 56.

.

 Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers@highlight

The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of leprosy.

 Two dose levels of the vaccine will be evaluated.

